niacinamide has been researched along with ponatinib in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 5 (38.46) | 2.80 |
| Authors | Studies |
|---|---|
| Damon, LE; Lasater, EA; Lin, KC; Salerno, S; Shah, NP; Smith, CC; Stewart, WK; Zhu, X | 1 |
| Andreeff, M; Cortes, J; Kantarjian, H; Pemmaraju, N; Ravandi, F | 1 |
| Fleischmann, M; Hilgendorf, I; Hochhaus, A; Sayer, HG; Schmidt, V; Schnetzke, U; Scholl, S; Schrenk, KG | 1 |
| Bonsignore, R; Gentile, C; Lauria, A; Martorana, A | 1 |
| Abegg, VF; Bouitbir, J; Grünig, D; Krähenbühl, S; Mingard, C; Paech, F | 1 |
| Lambrecht, AM; Larocque, EA; Naganna, N; Opoku-Temeng, C; Sintim, HO | 1 |
| Becker, JR; Force, T; Galindo, CL; Glennon, MS; Gupte, M; Lal, H; Singh, AP; Umbarkar, P; Zhang, Q | 1 |
| Antelope, O; Bowler, AD; Cayuela, JM; Clair, P; Deininger, MW; Druker, BJ; Eide, CA; Heinrich, MC; Kelley, TW; Kim, DW; O'Hare, T; Pomicter, AD; Qiang, W; Rea, D; Savage Stevens, SL; Schultz, AR; Senina, AV; Szankasi, P; Than, H; Tognon, CE; Tyner, JW; Vellore, NA; Yan, D; Zabriskie, MS | 1 |
| Gao, H; Qiu, Y; Rao, Y; Sun, X; Sun, Y; Weng, Q; Yang, Y | 1 |
| Cortes, J; Lang, F | 1 |
| Batista, R; Bouscary, D; Cayuela, JM; Chapuis, N; Contejean, A; Decroocq, J; Goldwirt, L; Tamburini, J; Willems, L; Zerbit, J | 1 |
| Alonso-Dominguez, JM; Alvarez-Larrán, A; Araujo, MC; Bitaube, RF; Boque, C; Carrascosa Mastell, P; Casado, LF; Cervero, C; Coll, AP; Cortes, M; Cuevas, B; De Las Heras, N; de Soria, VGG; Escola, A; Fernández, MJ; García-Gutiérrez, V; Garcia-Hernandez, C; García-Noblejas, A; Giraldo, P; Hernandez-Boluda, JC; Jiménez-Velasco, A; Lakhwani, S; Luna, A; Mora, E; Pérez-Encinas, M; Pérez-Lamas, L; Perez-Lopez, R; Ramila, E; Rosell, A; Ruiz Nuño, C; Sagüés, M; Salamanca, A; Sanchez-Guijo, F; Serrano, L; Steegmann, JL; Suarez-Varela, S; Vall-Llovera, F; Vega, MM; Vélez, P; Vera Goñi, JA; Villalon, L; Xicoy, B | 1 |
| Alos, HC; Audira, G; Aventurado, CA; Hsiao, CD; Lai, YH; Lim, KH; Lin, HC; Roldan, MJM; Saputra, F; Tsai, GJ; Vasquez, RD | 1 |
3 review(s) available for niacinamide and ponatinib
| Article | Year |
|---|---|
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridazines; Sorafenib; Staurosporine | 2014 |
Kinase Inhibitors in Multitargeted Cancer Therapy.
Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2017 |
Third-line therapy for chronic myeloid leukemia: current status and future directions.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Clinical Trials as Topic; Fusion Proteins, bcr-abl; Homoharringtonine; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Niacinamide; Nitriles; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Quinolines | 2021 |
10 other study(ies) available for niacinamide and ponatinib
| Article | Year |
|---|---|
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
Topics: Amino Acid Sequence; Amino Acid Substitution; Benzothiazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Molecular Docking Simulation; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridazines; Quinolines; Sorafenib | 2013 |
Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Imidazoles; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridazines; Retrospective Studies; Sorafenib; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells.
Topics: Adenosine Triphosphate; Animals; Apoptosis; Cytochromes c; Electron Transport; Hep G2 Cells; Humans; Imidazoles; Lysosomes; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; Mitochondria, Liver; Mitophagy; Necrosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridazines; Pyridines; Sorafenib | 2018 |
Alkynylnicotinamide-Based Compounds as ABL1 Inhibitors with Potent Activities against Drug-Resistant CML Harboring ABL1(T315I) Mutant Kinase.
Topics: Alkynes; Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Imatinib Mesylate; Imidazoles; Isoquinolines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Docking Simulation; Naphthyridines; Niacinamide; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyridazines; Quinazolines | 2018 |
Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies.
Topics: Animals; Animals, Genetically Modified; Antineoplastic Agents; Apoptosis; Cardiotoxicity; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Heart Diseases; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myocytes, Cardiac; Natriuretic Peptide, Brain; Niacinamide; Proof of Concept Study; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridazines; Rats; Signal Transduction; Zebrafish | 2019 |
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
Topics: Allosteric Regulation; Animals; Antineoplastic Combined Chemotherapy Protocols; Binding Sites; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Targeted Therapy; Mutation; Niacinamide; Primary Cell Culture; Pyrazoles; Pyridazines | 2019 |
Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects.
Topics: Antineoplastic Agents; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Humans; Imidazoles; Models, Molecular; Niacinamide; Proteolysis; Pyrazoles; Pyridazines | 2020 |
Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Fusion Proteins, bcr-abl; Humans; Imidazoles; Niacinamide; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrazoles; Pyridazines | 2021 |
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Niacinamide; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Retrospective Studies | 2022 |
Investigating Potential Cardiovascular Toxicity of Two Anti-Leukemia Drugs of Asciminib and Ponatinib in Zebrafish Embryos.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Monophenol Monooxygenase; Niacinamide; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Zebrafish | 2022 |